“…1–8 As such, they are considered valuable alternatives to Pt-based drugs. 1–8 To date, several Co- and Cu-based complexes including 4′- p -tolyl-(2,2′:6′,2′′- terpyridyl)triphenyl phosphonium bromide Cu( ii ), 1 morpholine-(iso)thiosemicarbazone Cu( ii ), 9 Cu II (thiosemi-carbazonato)Cl, 10 2-pyridylketonethiosemicarbazone Cu( ii ), 11 piperidylthiosemicarbazone Cu( ii ), 12 dasatinib Cu( ii ), 13 pyrrolizine Cu( ii ), 14 S-substituted dithiocarbazate Schiff-base Cu( ii ), 15 GSH-depleted bimetallic Cu( ii ), 16 thiosemicarbazone Cu( ii ), 17,18 carbohydrazone Cu( ii ), 19 Cu( ii ), and Co( ii ) phenanthroline, 20–25 oxygen-donor-rich-ligand Co( ii ) and Cu( ii ), 26,27 8-hydroxy-quinoline Co( iii ) and Cu( ii ), 28,29 oxoisoaporphine Co( ii ), 30 2,2′-bipyridine derivative Co( ii ) and Cu( ii ), 31–37 and tris(2-pyridylmethyl)amine-activated Co( ii ) and Cu( ii ) complexes, 38–42 among others, 43–46 have been proposed as antitumor agents that are as effective as cisplatin and its analogs. 1–8 However, none of these proposed drugs has been approved for clinical use.…”